Tech Company Financing Transactions
FLX Bio Funding Round
Celgene, GV and Kleiner Perkins Caufield & Byers invested in a $60 million Series C capital raise for FLX Bio. The financing round closed on 12/22/2017.
Transaction Overview
Company Name
Announced On
12/22/2017
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series C
Proceeds Purpose
In addition to initiating Phase 1 testing for our lead molecule FLX475, a highly potent and selective oral CCR4 antagonist for the treatment of cancer, we intend to select a clinical candidate targeting USP7 and continue advancement of our GCN2 program, with all three programs representing differentiated and important mechanisms to stimulate an immune response within the tumor microenvironment.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
561 Eccles Ave.
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Wong
Chief Medical Officer
William Ho
Chief Operating Officer
Rekha Hemrajani
Vice President
Dirk Brockstedt
Vice President
Paul Kassner
Vice President
David Wustrow
Browse more venture capital transactions:
Prev: 12/22/2017: TARIS Biomedical venture capital transaction
Next: 12/22/2017: Aura Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs